The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO GI 2023 | OREIOS: real-world registry of patients with unresectable HCC
Stephen Lam Chan, MBBS, Chinese University of Hong Kong, Hong Kong, China, provides an overview of the OREIOS study (NCT05239507), a real-world retrospective study designed to describe the management patterns, clinical characteristics, possible predictors, and survival outcomes in patients with unresectable hepatocellular carcinoma (HCC). Transarterial chemoembolisation (TACE) was found to be predominantly used over systemic therapy in intermediate stage HCC. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Gastrointestinal Cancers (GI) Symposium in San Francisco, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
